Navigating Recent Clinical Trial Results: Cardiovascular Risk Reduction in a Patient with Peripheral Artery Disease and Diabetes
59 year-old male presents for follow-up in clinic.
PMH: Hypertension, lower extremity peripheral artery disease (PAD), type 2 diabetes
Social History: non-smoker, no alcohol
aspirin 81 mg PO daily
cilostazol 100 mg PO twice daily
lisinopril/hydrochlorothiazide 20 mg/12.5 mg 2 tablets PO daily
metformin 1000 mg PO twice daily
rosuvastatin 20 mg PO daily
Vitals: BP: 142/96 mm Hg, P: 68 beats per minute, BMI 28.7 kg/m2
Labs: Kidney/liver function normal, A1C: 8.3%
Lipids (mg/dL): Total Cholesterol: 148, Triglycerides: 180, HDL-C: 42, LDL-C: 70
The patient states adherence with appropriate dietary habits.
During the clinician-patient discussion at today's visit, you express concern about the patient's high atherosclerotic cardiovascular disease risk. The patient states he is willing to take additional oral medications to lower his risk.
Which ONE of the following medications will be the best addition to the patient's current regimen to lower his patient's cardiovascular risk and blood glucose?